- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01104857
Respiratory Muscle Dysfunction in Critically Ill Patients
Respiratory muscle dysfunction in critically ill patients is associated with elevated morbidity, including prolonged weaning from mechanical ventilation. The causes for respiratory muscle dysfunction in these patients is poorly understood and no effective treatment is available.
The general hypothesis of the present study is that in critically ill mechanically ventilated subjects respiratory muscle dysfunctions results from loss of myosin induced by activation of proteolytic cascades.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Nijmegen, Netherlands, 6500HB
- Radboud Universtity Nijmegen Medical Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Severe sepsis / septic shock
- Clinical reason for laparotomy
- > 18 years
Exclusion Criteria:
- No informed consent
- Medical history of myopathy
- Unintended weight loss before ICU admission
- Pregnancy
- Chronic use of corticosteroids
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Diaphragm muscle biopsy
Patients admitted to the ICU meeting severe sepsis / septic shock criteria
|
Biopsy is obtained for biochemical analysis
|
|
Active Comparator: Elective laparotomy
|
Biopsy is obtained for biochemical analysis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diaphragm muscle myosin content
Time Frame: 1 day
|
1 day
|
|
|
Markers for inflammation
Time Frame: 1 day
|
Inflammatory mediators are measured in plasma and diaphragm at the moment the diaphragm biopsy is obtained.
|
1 day
|
|
Markers for activation of proteolytic pathway in the diaphragm
Time Frame: 1 day
|
Biochemical analysis is targeted towards activation of several proteolytic pathways (proteasome, lysosmal).
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
length of ICU stay
Time Frame: 6 months
|
Length of ICU stay obtained from medical record
|
6 months
|
|
Length of mechanical ventilation
Time Frame: 6 months
|
Duration of mechanical ventilation is assesssed within 6 months after obtaining diaphragm biopsy.
|
6 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- Diam1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.